Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Athenex, Inc. stock logo
ATNX
Athenex
$0.95
$0.20
$23.80
$1.76M1.36194,316 shs1.88 million shs
Endo International plc stock logo
ENDP
Endo International
$0.00
$0.45
$0.28
$7.07
$141K1.1528.19 million shs14,790 shs
Travere Therapeutics, Inc. stock logo
RTRX
Travere Therapeutics
$5.26
-2.4%
$26.56
$8.98
$24.96
$268.53M0.67412,277 shs1.22 million shs
Zogenix, Inc. stock logo
ZGNX
Zogenix
$26.68
$26.52
$11.03
$26.90
$1.50B0.893.76 million shs94 shs
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Athenex, Inc. stock logo
ATNX
Athenex
0.00%0.00%0.00%0.00%-82.49%
Endo International plc stock logo
ENDP
Endo International
0.00%0.00%+20.00%0.00%-99.09%
Travere Therapeutics, Inc. stock logo
RTRX
Travere Therapeutics
-1.10%-7.07%-28.80%-41.09%-74.32%
Zogenix, Inc. stock logo
ZGNX
Zogenix
0.00%0.00%0.00%0.00%0.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Athenex, Inc. stock logo
ATNX
Athenex
N/AN/AN/AN/AN/AN/AN/AN/A
Endo International plc stock logo
ENDP
Endo International
N/AN/AN/AN/AN/AN/AN/AN/A
Travere Therapeutics, Inc. stock logo
RTRX
Travere Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Zogenix, Inc. stock logo
ZGNX
Zogenix
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Athenex, Inc. stock logo
ATNX
Athenex
N/AN/AN/AN/A
Endo International plc stock logo
ENDP
Endo International
N/AN/AN/AN/A
Travere Therapeutics, Inc. stock logo
RTRX
Travere Therapeutics
N/AN/AN/AN/A
Zogenix, Inc. stock logo
ZGNX
Zogenix
N/AN/AN/AN/A

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Athenex, Inc. stock logo
ATNX
Athenex
$102.82M0.00N/AN/A($3.07) per share0.00
Endo International plc stock logo
ENDP
Endo International
$2.99B0.00$0.01 per share0.06($13.60) per share0.00
Travere Therapeutics, Inc. stock logo
RTRX
Travere Therapeutics
$175.34M1.53N/AN/A$5.15 per share1.02
Zogenix, Inc. stock logo
ZGNX
Zogenix
$81.69M18.36N/AN/A$6.64 per share4.02

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Athenex, Inc. stock logo
ATNX
Athenex
-$103.43M-$15.88N/AN/AN/A-86.31%-727.79%-44.44%N/A
Endo International plc stock logo
ENDP
Endo International
-$613.24M-$11.07N/A0.00N/A-93.31%-34.25%6.72%N/A
Travere Therapeutics, Inc. stock logo
RTRX
Travere Therapeutics
-$146.43M-$3.46N/AN/AN/A-49.13%-36.38%-14.90%N/A
Zogenix, Inc. stock logo
ZGNX
Zogenix
-$209.38M-$4.07N/AN/AN/A-278.38%-91.20%-43.60%N/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Athenex, Inc. stock logo
ATNX
Athenex
N/AN/AN/AN/AN/A
Endo International plc stock logo
ENDP
Endo International
N/AN/AN/AN/AN/A
Travere Therapeutics, Inc. stock logo
RTRX
Travere Therapeutics
N/AN/AN/AN/AN/A
Zogenix, Inc. stock logo
ZGNX
Zogenix
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Athenex, Inc. stock logo
ATNX
Athenex
3.08
1.09
0.72
Endo International plc stock logo
ENDP
Endo International
N/A
1.86
1.62
Travere Therapeutics, Inc. stock logo
RTRX
Travere Therapeutics
0.66
7.23
7.14
Zogenix, Inc. stock logo
ZGNX
Zogenix
0.88
3.63
4.74

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Athenex, Inc. stock logo
ATNX
Athenex
30.48%
Endo International plc stock logo
ENDP
Endo International
80.39%
Travere Therapeutics, Inc. stock logo
RTRX
Travere Therapeutics
N/A
Zogenix, Inc. stock logo
ZGNX
Zogenix
N/A

Insider Ownership

CompanyInsider Ownership
Athenex, Inc. stock logo
ATNX
Athenex
9.20%
Endo International plc stock logo
ENDP
Endo International
1.20%
Travere Therapeutics, Inc. stock logo
RTRX
Travere Therapeutics
4.63%
Zogenix, Inc. stock logo
ZGNX
Zogenix
4.10%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Athenex, Inc. stock logo
ATNX
Athenex
6528.66 million7.87 millionOptionable
Endo International plc stock logo
ENDP
Endo International
3,103235.14 million232.32 millionNo Data
Travere Therapeutics, Inc. stock logo
RTRX
Travere Therapeutics
22151.05 millionN/ANot Optionable
Zogenix, Inc. stock logo
ZGNX
Zogenix
21856.23 million53.92 millionOptionable

ENDP, ZGNX, ATNX, and RTRX Headlines

SourceHeadline
Hwasung Industrial Co Ltd 002460Hwasung Industrial Co Ltd 002460
morningstar.com - March 23 at 1:30 AM
Orally Inhaled DihydroergotamineOrally Inhaled Dihydroergotamine
medscape.com - February 13 at 4:11 PM
MRI in HeadacheMRI in Headache
medscape.com - August 25 at 10:47 PM
Kratom: What We KnowKratom: What We Know
medscape.com - August 13 at 5:03 PM
Alcon (NYSE: ALC)Alcon (NYSE: ALC)
fool.com - July 6 at 8:34 PM
Longeveron Inc Ordinary Shares - Class ALongeveron Inc Ordinary Shares - Class A
morningstar.com - May 21 at 12:24 AM
Dravet Syndrome Market Report 2032: Epidemiology Data, Pipeline ... - Digital JournalDravet Syndrome Market Report 2032: Epidemiology Data, Pipeline ... - Digital Journal
news.google.com - May 10 at 11:58 PM
Global Needle Free Diabetes Management Market Size 2023 ... - The Northwestern ExaminerGlobal Needle Free Diabetes Management Market Size 2023 ... - The Northwestern Examiner
news.google.com - May 8 at 2:44 PM
Global Needle-Free Drug Delivery Systems Market New ... - The Northwestern ExaminerGlobal Needle-Free Drug Delivery Systems Market New ... - The Northwestern Examiner
news.google.com - May 8 at 2:44 PM
Needle Free Injection Systems Market Size Reach Valuation of USD 519.3 Million in 2030 - Emergen Research - openPRNeedle Free Injection Systems Market Size Reach Valuation of USD 519.3 Million in 2030 - Emergen Research - openPR
news.google.com - May 4 at 4:03 PM
Needle Free Diabetes Management Market Forecast 2023 – 2032 ... - Taiwan NewsNeedle Free Diabetes Management Market Forecast 2023 – 2032 ... - Taiwan News
news.google.com - April 28 at 12:42 PM
The Pathophysiological and Pharmacological Basis of Current Drug Treatment of Migraine HeadacheThe Pathophysiological and Pharmacological Basis of Current Drug Treatment of Migraine Headache
medscape.com - April 25 at 2:50 PM
Long-Acting Injectable Antipsychotics Market 2023-2033: Global ... - Taiwan NewsLong-Acting Injectable Antipsychotics Market 2023-2033: Global ... - Taiwan News
news.google.com - April 24 at 9:21 AM
Anti-epileptic Drugs Market Expected to Expand at a Steady 2023 ... - Digital JournalAnti-epileptic Drugs Market Expected to Expand at a Steady 2023 ... - Digital Journal
news.google.com - April 24 at 9:21 AM
Dravet Syndrome Pipeline Assessment (2023 Updates) | In-depth ... - Digital JournalDravet Syndrome Pipeline Assessment (2023 Updates) | In-depth ... - Digital Journal
news.google.com - April 20 at 12:29 AM
Form SC 14D9/A Provention Bio, Inc. Filed by: Provention Bio, Inc. - StreetInsider.comForm SC 14D9/A Provention Bio, Inc. Filed by: Provention Bio, Inc. - StreetInsider.com
news.google.com - April 19 at 7:28 PM
DEA lifts Dravet therapy Finteplas controlled substance status |... - Dravet Syndrome NewsDEA lifts Dravet therapy Fintepla's controlled substance status |... - Dravet Syndrome News
news.google.com - April 18 at 3:52 PM
UCB Announces FINTEPLA® (fenfluramine) Oral Solution Is Now ... - Longview News-JournalUCB Announces FINTEPLA® (fenfluramine) Oral Solution Is Now ... - Longview News-Journal
news.google.com - April 17 at 7:30 PM
Subcutaneous Medicine Delivery Devices Market is poised to grow ... - Digital JournalSubcutaneous Medicine Delivery Devices Market is poised to grow ... - Digital Journal
news.google.com - April 17 at 7:30 PM
Epilepsy Market to Observe Utmost CAGR of 7.78% by 2028, Size ... - Digital JournalEpilepsy Market to Observe Utmost CAGR of 7.78% by 2028, Size ... - Digital Journal
news.google.com - April 17 at 9:27 AM
UCB Announces FINTEPLA® (fenfluramine) Oral Solution Is Now ... - PR NewswireUCB Announces FINTEPLA® (fenfluramine) Oral Solution Is Now ... - PR Newswire
news.google.com - April 17 at 9:27 AM
Lennox Gastaut Syndrome Market to Witness Growth by 2032 | Companies-GlaxoSmithKline, Meda Pharmaceuticals, Ro - openPRLennox Gastaut Syndrome Market to Witness Growth by 2032 | Companies-GlaxoSmithKline, Meda Pharmaceuticals, Ro - openPR
news.google.com - April 14 at 8:40 AM
Needle-Free Injectors Market Robust Expansion is expected to 2030 - Digital JournalNeedle-Free Injectors Market Robust Expansion is expected to 2030 - Digital Journal
news.google.com - April 13 at 5:40 PM
New Trends of Long-acting Injectable Medications Market Demand: Insights and Analysis from Latest Research Rep - openPRNew Trends of Long-acting Injectable Medications Market Demand: Insights and Analysis from Latest Research Rep - openPR
news.google.com - April 12 at 1:29 PM

New MarketBeat Followers Over Time

Company Descriptions

Athenex logo

Athenex

NASDAQ:ATNX
Athenex, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapies for the treatment of cancer. It operates through the Oncology Innovation Platform and Commercial Platform segments. The Oncology Innovation Platform segment focuses on the research and development of proprietary drugs. The Commercial Platform segment covers the sale and market of specialty drugs and market development of proprietary drugs. The company was founded by Lyn M. Dyster and David G. Hangauer in November 2003 and is headquartered in Buffalo, NY.
Endo International logo

Endo International

NASDAQ:ENDP
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. Its Branded Pharmaceuticals segment provides branded prescription products, including XIAFLEX to treat adult patients with Dupuytren's contracture; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL nasal spray to treat vitamin B12 deficiency; AVEED to treat hypogonadism; QWO, an injectable treatment for moderate to severe cellulite in the buttocks of adult women; PERCOCET to treat moderate-to-moderately-severe pain; TESTOPEL an implantable pellet indicated for TRT in conditions associated with a deficiency or absence of endogenous testosterone; EDEX to treat erectile dysfunction; LIDODERM a topical patch product containing lidocaine for the relief of pain; and products for the pain management and urology. The company's Sterile Injectables segment manufactures VASOSTRICT, a vasopressin injection; ADRENALIN, a non-selective adrenergic agonist; and APLISOL, which is a sterile aqueous solution, as well as generic sterile injectable products, including ertapenem for injections and ephedrine sulfate injections. Its Generic Pharmaceuticals segment offers solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmic products, and sprays. The company's International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas comprising attention deficit hyperactivity disorder, pain, women's health, oncology, and transplantation. The company sells its branded pharmaceuticals and generics to specialty physicians, retailers, clinics, government agencies, doctors, retail and specialty pharmacies, and specialty distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland.
Travere Therapeutics logo

Travere Therapeutics

NASDAQ:RTRX
Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. Its products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 8, 2008 and is headquartered in San Diego, CA.
Zogenix logo

Zogenix

NASDAQ:ZGNX
Zogenix, Inc. is a pharmaceutical company. The firm engages in the development and commercialization of central nervous system (CNS) therapies and products for the treatment orphan diseases and other CNS disorders. Its products include Fintepla and MT1621. The company was founded by Stephen James Farr, Cam L. Garner, Roger L. Hawley, Bret E. Megargel, Jonathan M. N. Rigby, Scott L. Glenn, and John J. Turanin on May 11, 2006 and is headquartered in Emeryville, CA.